|
|
|
|
 |
| |
|
|
CRM OFFICE LAUNCH BY MINISTER OF HEALTH AND MOU SIGNING CEREMONY
Thursday 21/02/2019
-MoU Signing between Clinical Research Malaysia & National University Hospital Singapore
-MoU Signing between Clinical Research Malaysia and CytoMed Therapeutics
-Opening Ceremony of Clinical Research Malaysia (CRM) New Office
Members of the media are cordially invited to attend the CRM Office launch by Minister of Health and MoU Signing Ceremony.
Details of the event are as below:
Day/Date: Tuesday 26 February 2019
Time: 10:30 am – 12:40 pm
Venue: Level 37, Menara SuezCap, KL Gateway (for Opening Ceremony will be held at Clinical Research Malaysia office at Level 26)
VIPs:
-YB Datuk Seri Dr. Dzulkefly Ahmad (Minister of Health, Malaysia)
-YBhg. Dato' Seri Dr. Chen Chaw Min (Secretary General, Ministry of Health, Malaysia)
-YBhg. Datuk Dr. Noor Hisham Abdullah (Director General of Health, Malaysia)
-YBhg. Datuk Dr. Shahnaz Murad (Board Member of Clinical Research Malaysia)
-YBhg. Dato' Dr. Goh Pik Pin (Director, National Clinical Research Centre)
-YBhg. Prof Datuk Dr. Adeeba Kamarulzaman (Dean of the Medical Faculty, University Malaya)
-Mr. Ewe Kheng Huat (Executive Director of PhAMA)
-Prof. Chng Wee Joo (Group Director of National University Hospital Singapore)
-Mr Choo Chee Kong (Director of CytoMed Therapeutics)
-Dr. Akhmal Yusof (Chief Executive Officer, Clinical Research Malaysia)
Programme
10:30 am: Arrival of media & guests
11:00 am: Opening of CRM’s New Office (Level 26) by Minister of Health
11:15 am: Adjourn to Level 37
MoU Signing Ceremony
11:40 am: Remarks by Mr Choo Chee Kong, Director of CytoMed Therapeutics
11:50 am: Remarks by Prof. Chng Wee Joo, Group Director of National University Hospital (Singapore)
12:00 pm: Remarks by YB Datuk Seri Dr. Dzulkefly Ahmad, Minister of Health, Malaysia
12:10 pm: MoU Signing Ceremony
-CytoMed Therapeutics
-National University Hospital (Singapore)
12:20 pm: Press Conference
12:40 pm: Adjourn for Lunch
About the National University Health System
The National University Health System (NUHS) is one of three public healthcare clusters in Singapore, and an integrated Academic Health System and Regional Health System that delivers value-driven, innovative and sustainable healthcare in Singapore.
Through collaborations with National University of Singapore (NUS) faculties, we are able to draw upon their academic, research and creative capabilities to develop solutions for existing and emerging health and healthcare needs.
As a Regional Health System, we work in close collaboration with community hospitals, general practitioners, family medicine clinics and other community partners to provide integrated care to the community.
With member institutions under one Academic Health System, NUHS creates synergies as a fully integrated cluster to provide seamless care, develop solutions for Singapore's healthcare challenges and nurture the next generation of healthcare professionals.
-National University Hospital
-Ng Teng Fong General Hospital
-Jurong Community Hospital
-Alexandra Hospital
-Jurong Medical Centre
-National University Cancer Institute, Singapore
-National University Heart Centre, Singapore
-National University Centre for Oral Health, Singapore
-National University Polyclinics
-NUS Yong Loo Lin School of Medicine
-NUS Alice Lee Centre for Nursing Studies
-NUS Faculty of Dentistry
-NUS Saw Swee Hock School of Public Health, Singapore
About the National University Cancer Institute, Singapore
The National University Cancer Institute, Singapore (NCIS) offers a broad spectrum of cancer care and management covering both paediatric and adult cancers, with expertise in prevention, screening, diagnosis, treatment, rehabilitation and palliative care. The Institute’s strength lies in the multi-disciplinary approach taken to develop a comprehensive and personalised plan for each cancer patient and his or her family.
With several award-winning clinician-scientists and clinician-investigators, NCIS has an international reputation in translational research and clinical trials, providing patients with access to promising breakthroughs in cancer diagnostics, technology and therapies. For more information about NCIS, please visit www.ncis.com.sg.
About CytoMed Therapeutics
Incorporated in 2018, CytoMed Therapeutics is a spin-off from Singapore’s Agency for Science, Technology and Research (A*Star) and focuses on translating its patented technologies into gamma delta (γδ) T cell- and natural killer (NK) cell-based “off-the-shelf” immunotherapeutics for a wide range of cancers. CytoMed also engages in generating induced pluripotent stem cells (iPSCs) and developing them into cellular therapeutics using our proprietary technologies for our customers. CytoMed believes that “off-the-shelf” cancer immunotherapeutics will be the future of cancer immunotherapy through lowering cost and allowing access of therapy to the masses. For more information, please visit www.cytomed.sg.
About Clinical Research Malaysia (CRM)
Established by the Malaysian Ministry of Health in 2012, CRM exists to advance global health solutions for a brighter, more hopeful future for the people by providing speedy and reliable end-to- end clinical research support for quality studies. CRM’s innate understanding of the local clinical research landscape with the international standards of operations coupled with fundamental backing of the government ministries provide us an incomparable advantage to work with partners from the nascent stages of development to materialisation of the end product, in order to deliver better treatment and high skilled job opportunities. For further information, please visit www.clinicalresearch.my/ctd18
You are cordially invited to send a reporter and photographer/cameraman to cover the MOU Signing Ceremony.
SOURCE: Clinical Research Malaysia (CRM)
FOR MORE INFORMATION AND RSVP, PLEASE CONTACT:
Name: Syed Hamzah Syed Noordin
Tel: +603 7931 5566 (ext. 120)
Email: hamzah@clinicalresearch.my
Website: http://www.clinicalresearch.my
-BERNAMA |
|
|
|
|
|
